The global deep brain stimulation devices market for Parkinson’s disease is estimated to reach US$ 135.6 Billion by 2021, growing at a CAGR of 7.2% from 2017 to 2021.
Parkinson’s disease (PD) affects an estimated one million Americans including men and women of all ages and races, though it is slightly more common in men. Parkinson’s is caused by a combination of genetic and environmental factors, with age being the main risk factor. There is no cure, but there are many excellent symptomatic treatments.
Deep brain stimulation (DBS) has become a well-established symptomatic treatment for Parkinson’s disease during the last 25 years. The therapy delivers electrical pulses to brain cells to decrease symptoms of Parkinson’s disease, especially if symptoms cannot be adequately controlled with medication. The electrical signals delivered by DBS de-activate the target site within the brain without destroying any tissue, restoring the balance of electrical activity within brain, to offset the progressive loss of cells caused by Parkinson’s. Older surgical therapies such as pallidotomy and thalamotomy can ease symptoms but have not been proven to change the underlying course of disease. Deep brain stimulation improves levodopa-responsive symptoms, dyskinesia, and tremor, where benefits are long-lasting in many motor domains. DBS uses a surgically implanted, battery-operated medical device called an implantable pulse generator (IPG) to deliver electrical stimulation to specific areas in the brain that control movement, thus blocking the abnormal nerve signals that cause PD symptoms.
Researchers are working to improve upon the existing DBS devices and surgical methods, including “smart” DBS with the goal of making the therapy beneficial for more symptoms and therefore for a greater number of people. Advances in the understanding of DBS mechanisms and improvements in the devices and surgical approaches are underway for a wider variety of people at different stages of Parkinson’s. Since its approval by the Food and Drug Administration for PD in 2002, more than 70,000 patients have undergone DBS surgery, according to Medtronic Inc. Nevertheless, there are ever-growing findings concerning the effectiveness of DBS and the pathomechanisms of side effects resulting in development of new devices and stimulation paradigms. The main aim is a further reduction of side effects and better adaption to individual courses of PD.
The global deep brain stimulation devices market for Parkinson’s disease report estimates the market size (Revenue US$ million – 2014 to 2021) by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World and forecasts growth trends (CAGR% – 2017 to 2021). The global deep brain stimulation devices market for Parkinson’s disease report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating the global deep brain stimulation devices market for Parkinson’s disease and profiled in this report include Aleva Neurotherapeutics, Boston Scientific Corporation, Medtronic Inc., and St. Jude Medical Inc.
1.1. North America (U.S., Canada)
1.2. Latin America (Brazil, Mexico, Rest of LA)
1.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
1.4. Asia Pacific (Japan, China, India, Rest of APAC)
1.5. Rest of the World
2. Company Profiles
2.1. Aleva Neurotherapeutics
2.2. Boston Scientific Corporation
2.3. Medtronic, Inc.
2.4. St. Jude Medical, Inc.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/deep-brain-stimulation-devices-parkinsons-disease-market/